Cargando…

Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma

Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic abil...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Weilin, Geng, Xin, Chen, Sidi, Tan, Lixing, Tan, Yulong, Wang, An, Lu, Zhouyi, Guo, Shicheng, Chen, Xiaofeng, Wang, Jiucun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166538/
https://www.ncbi.nlm.nih.gov/pubmed/27994665
http://dx.doi.org/10.7150/jca.15758
_version_ 1782483048137228288
author Pu, Weilin
Geng, Xin
Chen, Sidi
Tan, Lixing
Tan, Yulong
Wang, An
Lu, Zhouyi
Guo, Shicheng
Chen, Xiaofeng
Wang, Jiucun
author_facet Pu, Weilin
Geng, Xin
Chen, Sidi
Tan, Lixing
Tan, Yulong
Wang, An
Lu, Zhouyi
Guo, Shicheng
Chen, Xiaofeng
Wang, Jiucun
author_sort Pu, Weilin
collection PubMed
description Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic ability of CDH13 methylation in NSCLC as well as in its subsets. Eligible studies were identified through searching PubMed, Web of Science, Cochrane Library and Embase. The pooled odds of CDH13 promoter methylation in lung cancer tissues versus normal controls were calculated by meta-analysis method. Simultaneously, four independent DNA methylation datasets of NSCLC from TCGA and GEO database were downloaded and analyzed to validate the results from meta-analysis. Results: Thirteen studies, including 1850 samples were included in this meta-analysis. The pooled odds ratio of CDH13 promoter methylation in cancer tissues was 7.41 (95% CI: 5.34 to 10.29, P < 0.00001) compared with that in controls under fixed-effect model. In validation stage, 126 paired samples from TCGA were analyzed and 5 out of the 6 CpG sites in the CpG island of CDH13 were significantly hypermethylated in lung adenocarcinoma tissues but none of the 6 CpG sites was hypermethylated in squamous cell carcinoma tissues. Concordantly, the results from other three datasets, which were subsequently obtained from GEO database consisting of 568 tumors and 256 normal tissues, also consisted with those from TCGA dataset. Conclusion: The pooled data showed that the methylation status of the CDH13 promoter is strongly associated with lung adenocarcinoma. The CDH13 methylation status could be a promising diagnostic biomarker for diagnosis of lung adenocarcinoma.
format Online
Article
Text
id pubmed-5166538
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-51665382016-12-19 Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma Pu, Weilin Geng, Xin Chen, Sidi Tan, Lixing Tan, Yulong Wang, An Lu, Zhouyi Guo, Shicheng Chen, Xiaofeng Wang, Jiucun J Cancer Research Paper Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic ability of CDH13 methylation in NSCLC as well as in its subsets. Eligible studies were identified through searching PubMed, Web of Science, Cochrane Library and Embase. The pooled odds of CDH13 promoter methylation in lung cancer tissues versus normal controls were calculated by meta-analysis method. Simultaneously, four independent DNA methylation datasets of NSCLC from TCGA and GEO database were downloaded and analyzed to validate the results from meta-analysis. Results: Thirteen studies, including 1850 samples were included in this meta-analysis. The pooled odds ratio of CDH13 promoter methylation in cancer tissues was 7.41 (95% CI: 5.34 to 10.29, P < 0.00001) compared with that in controls under fixed-effect model. In validation stage, 126 paired samples from TCGA were analyzed and 5 out of the 6 CpG sites in the CpG island of CDH13 were significantly hypermethylated in lung adenocarcinoma tissues but none of the 6 CpG sites was hypermethylated in squamous cell carcinoma tissues. Concordantly, the results from other three datasets, which were subsequently obtained from GEO database consisting of 568 tumors and 256 normal tissues, also consisted with those from TCGA dataset. Conclusion: The pooled data showed that the methylation status of the CDH13 promoter is strongly associated with lung adenocarcinoma. The CDH13 methylation status could be a promising diagnostic biomarker for diagnosis of lung adenocarcinoma. Ivyspring International Publisher 2016-11-25 /pmc/articles/PMC5166538/ /pubmed/27994665 http://dx.doi.org/10.7150/jca.15758 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Pu, Weilin
Geng, Xin
Chen, Sidi
Tan, Lixing
Tan, Yulong
Wang, An
Lu, Zhouyi
Guo, Shicheng
Chen, Xiaofeng
Wang, Jiucun
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
title Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
title_full Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
title_fullStr Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
title_full_unstemmed Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
title_short Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
title_sort aberrant methylation of cdh13 can be a diagnostic biomarker for lung adenocarcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166538/
https://www.ncbi.nlm.nih.gov/pubmed/27994665
http://dx.doi.org/10.7150/jca.15758
work_keys_str_mv AT puweilin aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT gengxin aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT chensidi aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT tanlixing aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT tanyulong aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT wangan aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT luzhouyi aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT guoshicheng aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT chenxiaofeng aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma
AT wangjiucun aberrantmethylationofcdh13canbeadiagnosticbiomarkerforlungadenocarcinoma